{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-297165","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.745323+00:00","generated_at":"2026-05-16T17:02:32.219283+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Stockholders approve 2025 equity plan and executive option repricing to $1.50","bullets":["2025 Stock Incentive Plan approved with 30.5M for, 2.9M against.","CEO René Russo's 2,198,212 options repriced from $5.76 to $1.50.","CFO Christopher Frankenfield's 848,172 options repriced from $4.67 to $1.50.","CMO Katarina Luptakova's 225,210 options repriced from $4.10 to $1.50; effective after market close Nov 21."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-297165","json":"https://secwatch.observer/filing/0001193125-25-297165.json","markdown":"https://secwatch.observer/filing/0001193125-25-297165.md","text":"https://secwatch.observer/filing/0001193125-25-297165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/0001193125-25-297165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/xlo-20251121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:02:32.219283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}